Drug Target Identification Using Side-Effect Similarity
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Targets for drugs have so far been predicted on the basis of molecular or cellular features, for example, by exploiting similarity in chemical structure or in activity across cell lines. We used phenotypic side-effect similarities to infer whether two drugs share a target. Applied to 746 marketed drugs, a network of 1018 side effect–driven drug-drug relations became apparent, 261 of which are formed by chemically dissimilar drugs from different therapeutic indications. We experimentally tested 20 of these unexpected drug-drug relations and validated 13 implied drug-target relations by in vitro binding assays, of which 11 reveal inhibition constants equal to less than 10 micromolar. Nine of these were tested and confirmed in cell assays, documenting the feasibility of using phenotypic information to infer molecular interactions and hinting at new uses of marketed drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The work of Campillios et al. previously suggested the similarity of two drugs’ side effect profiles is positively correlated with the probability that these drugs share a common target28.”
From OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models (2025) · cites this paper as [28]
Citations
Cites
The unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
Docking and scoring in virtual screening for drug discovery: methods and applications
Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1549 · Cited by 4,150
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Gohlke, H., & Klebe, G. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020802)41:15<2644::aid-anie2644>3.0.co;2-o · Cited by 843
Global mapping of pharmacological space
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., Mason, J. S., & Hopkins, A. L. (2006) · Nature Biotechnology · doi:10.1038/nbt1228 · Cited by 811
Do Structurally Similar Molecules Have Similar Biological Activity?
Martin, Y. C., Kofron, J. L., & Traphagen, L. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020155c · Cited by 806
SuperTarget and Matador: resources for exploring drug-target relationships
Gunther, S., Kuhn, M., Dunkel, M., Campillos, M., Senger, C., Petsalaki, E., Ahmed, J., Urdiales, E. G., Gewiess, A., Jensen, L. J., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm862 · Cited by 647
Self-citation
Research works printed but not linked: 3
- J. Blagg, Annu. Rep. Med. Chem.41, 353 (2006).
- S. Guntheret al., Nucleic Acids Res.36, D919 (2008).
- C. M. Krejsaet al., Curr. Opin. Drug Discov. Dev.6, 470 (2003).
Cited by
Items 601–700 of 1,000
Predicting drug side effects based on link prediction in bipartite network
Luo, Y., Liu, Q., Wu, W., Li, F., & Bo, X. (2014) · International Conference on Biomedical Engineering and Informatics (BMEI) · doi:10.1109/bmei.2014.7002869 · Cited by 25
“In this study, we construct a drug - side effect network based on the clinical drug reactions, and transform the side effect inference to a link prediction problem in the complex network[12].”
MethodComputational Systems Chemical Biology
Oprea, T. I., May, E. E., Leitão, A., & Tropsha, A. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-839-3_18 · Cited by 28
“…2211 drugs experimentally tested on 188 targets from the same experimental source (CEREP), those 5 class A GPCR amines and 5HTT, i.e., the targets disclosed for 12 of these 13 “unexpected” findings (Campillos et al., 2008), were found to bind, on average, to over 440 (out of 2211) small molecules.”
BackgroundMethodInfluentialWang, K., Wan, M., Wang, R., & Weng, Z. (2016) · Journal of Medical Internet Research · doi:10.2196/jmir.4541 · Cited by 24
“Other than these strategies primarily focused on preclinical information, side effects data are increasingly used for rational drug repositioning [8-10], due to the direct reflection of the clinical reality of actual patients [11].”
Disease gene identification based on generic and disease-specific genome networks
Nam, Y., Jhee, J. H., Cho, J., Lee, J., & Shin, H. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty882 · Cited by 27
Lee, K. H., Fant, A. D., Guo, J., Guan, A., Jung, J., Kudaibergenova, M., Miranda, W. E., Ku, T. C., Cao, J., Wacker, S., et al. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00856 · Cited by 24
Network based Approach to Drug Discovery: A Mini Review
Li, P., Fu, Y., & Wang, Y. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666150219143933 · Cited by 26
“proposed a systematic method to relate drugs to each other based on the assumption that drugs with similar side-effects are likely to interact with similar target proteins [22].”
MethodARWAR: A network approach for predicting Adverse Drug Reactions
Rahmani, H., Weiß, G., Méndez‐Lucio, O., & Bender, A. (2015) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2015.11.005 · Cited by 24
“The second category of methods relates drug side-effects to its protein targets [9,14,34].”
BackgroundProceedings of The 5th Workshop on BioNLP Open Shared Tasks
Kim, J.-D., Nédellec, C., Bossy, R., & Deléger, L. (2019) · doi:10.18653/v1/d19-57 · Cited by 29
Issa, N. T., Kruger, J., Wathieu, H., Raja, R., Byers, S. W., & Dakshanamurthy, S. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1065-y · Cited by 22
“Initiatives utilizing network analysis have led to successful drug discovery efforts [6–11].”
MethodEmpowering industrial research with shared biomedical vocabularies
Harland, L., Larminie, C. G. C., Sansone, S., Popa, S., Marshall, M. S., Braxenthaler, M., Cantor, M. N., Filsell, W., Forster, M. J., Huang, E. S., et al. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.013 · Cited by 22
Effectively Identifying Compound-Protein Interaction Using Graph Neural Representation
Lin, X., Quan, Z., Wang, Z.-J., Guo, Y. P., Zeng, X., & Yu, P. S. (2022) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2022.3198003 · Cited by 23
“CPI prediction has received much attention in recent years [7], [8], [9].”
BackgroundPNImodeler: web server for inferring protein-binding nucleotides from sequence data
Im, J., Tuvshinjargal, N., Park, B., Lee, W., Huang, D.-S., & Han, K. (2015) · BMC Genomics · doi:10.1186/1471-2164-16-s3-s6 · Cited by 22
A Survey on Evolutionary Algorithm Based Hybrid Intelligence in Bioinformatics
Li, S., Kang, L., & Zhao, X. (2014) · BioMed Research International · doi:10.1155/2014/362738 · Cited by 29
“Except for diagnosis, intelligent methods have been exploited to identify biomarkers [5], annotate gene functions [6], predict drug targets [7, 8], and reverse engineering signaling pathways [9], among others.”
MethodHenriksen, K., Christiansen, C., & Karsdal, M. A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.010 · Cited by 22
Chemoisosterism in the Proteome
Jalencas, X., & Mestres, J. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci3002974 · Cited by 22
Ye, F. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1020788 · Cited by 22
“Phenotype-based virtual screening begins with text mining of published information to extract clinical or experimental phenotypes (e.g., side-effect labels) of drug molecules, and then to predict their target(s) based on phenotype similarity [23,24] .”
Backgroundvan der Horst, E., Peironcely, J. E., van Westen, G. J. P., van den Hoven, O. O., Galloway, W. R. J. D., Spring, D. R., Wegner, J. K., van Vlijmen, H., IJzerman, A. P., Overington, J. P., et al. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611796391230 · Cited by 23
“Recently publications have appeared which go back from observed adverse drug reactions to a common underlying mechanism of action [68], and in our studies we focused on a chemogenomics-based target prediction of compounds with an adverse drug reaction as annotated in the World Drug Index [52].”
Predicting gastrointestinal drug effects using contextualized metabolic models
Guebila, M. B., & Thiele, I. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007100 · Cited by 22
Cao, R., & Wang, Y. (2015) · ChemMedChem · doi:10.1002/cmdc.201500228 · Cited by 21
APT drug R&D: the right active ingredient in the right presentation for the right therapeutic use
Cavalla, D. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2981 · Cited by 22
Training Translators for Smart Drug Discovery
Skarke, C., & FitzGerald, G. A. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000890 · Cited by 24
Extended Multitarget Pharmacology of Anticancer Drugs
Shi, D., Khan, F., & Abagyan, R. A. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00031 · Cited by 25
“With those two matrices and the following equations (3) to (5), distances between pairs of targets were calculated.”
BackgroundPrincipled multi-omic analysis reveals gene regulatory mechanisms of phenotype variation
Hanson, C. R., Cairns, J., Wang, L., & Sinha, S. (2018) · Genome Research · doi:10.1101/gr.227066.117 · Cited by 32
“A panoply of studies has sought to identify mechanisms of action of specific drugs (1) (2) (3) (4) (5) as well as genotypic variations that are predictive of an individual’s drug response (6) (7) (8).”
BackgroundLi, G., Yang, L., Xu, Y., Wang, W., Li, L., & Yang, S. (2013) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2013.07.005 · Cited by 21
Towards the Next Generation of Computational Chemogenomics Tools
Rognan, D. (2013) · Molecular Informatics · doi:10.1002/minf.201300054 · Cited by 22
FacPad: Bayesian sparse factor modeling for the inference of pathways responsive to drug treatment
Ma, H., & Zhao, H. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts502 · Cited by 21
Quantitative prediction of drug side effects based on drug-related features
Niu, Y., & Zhang, W. (2017) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-017-0236-5 · Cited by 23
Yang, C. C., & Zhao, M. (2019) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2019.03.003 · Cited by 24
Applications of Machine Learning in Drug Target Discovery
Gao, D., Chen, Q., Zeng, Y., Jiang, M., & Zhang, Y. (2020) · Current Drug Metabolism · doi:10.2174/1567201817999200728142023 · Cited by 26
Compound Functional Prediction Using Multiple Unrelated Morphological Profiling Assays
Rose, F., Basu, S., Rexhepaj, E., Chauchereau, A., Nery, E. D., & Genovesio, A. (2017) · SLAS TECHNOLOGY · doi:10.1177/2472630317740831 · Cited by 25
Arooj, M., Sakkiah, S., Cao, G. P., Kim, S., Arulalapperumal, V., & Lee, K. W. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24677 · Cited by 23
Multimodal network diffusion predicts future disease–gene–chemical associations
Lin, C.-H., Konecki, D. M., Liu, M., Wilson, S. J., Nassar, H., Wilkins, A. D., Gleich, D. F., & Lichtarge, O. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty858 · Cited by 21
Computational Bioactivity Fingerprint Similarities To Navigate the Discovery of Novel Scaffolds
Xiong, G., Zhao, Y., Liu, L., Ma, Z.-Y., Lü, A., Cheng, Y., Hou, T., & Cao, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00234 · Cited by 21
Identifying and characterizing promiscuous targets: Implications for virtual screening
Pérez‐Nueno, V. I., & Ritchie, D. W. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.632406 · Cited by 20
“Considerable effort is now being put into the computational [5,6] and experimental [7,8] screening of suspected off-target proteins in the hope that side effects might be identified early, before the cost associated with developing a drug candidate rises steeply [9] .”
BackgroundMethodYeast “N”-hybrid systems for protein–protein and drug–protein interaction discovery
Rezwan, M., & Auerbach, D. (2012) · Methods · doi:10.1016/j.ymeth.2012.06.006 · Cited by 24
Xu, R., & Wang, Q. (2013) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2012-001584 · Cited by 21
Systems Pharmacology: A Unified Framework for Prediction of Drug-Target Interactions
Le, D., & Le, L. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160418121534 · Cited by 20
DrPOCS: Drug Repositioning Based on Projection Onto Convex Sets
Wang, Y., Cui, C., Qi, L., Yan, H., & Zhao, X. (2018) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2018.2830384 · Cited by 20
“[5], [6], [7], [8], [9].”
Computational medicine: quantitative modeling of complex diseases
Tiwary, B. K. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz005 · Cited by 22
Quantitative Signal Detection and Analysis in Pharmacovigilance
Bate, A., Pariente, A., Hauben, M., & Bégaud, B. (2014) · Wiley eBooks · doi:10.1002/9781118820186.ch20 · Cited by 20
Curation and Analysis of Multitargeting Agents for Polypharmacological Modeling
Reddy, A. S., Tan, Z., & Zhang, S. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500092j · Cited by 20
Protein homology reveals new targets for bioactive small molecules
Gfeller, D., & Zoete, V. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv214 · Cited by 23
Sharma, A., & Rani, R. (2018) · Journal of Intelligent & Fuzzy Systems · doi:10.3233/jifs-169713 · Cited by 20
Wang, K., Sun, J., Zhou, S., Wan, C., Qin, S., Li, C., He, L., & Yang, L. (2013) · PLoS Computational Biology · doi:10.1371/annotation/958d4c23-4f1e-4579-b6ef-8ae1f828b1dd · Cited by 20
Can the vector space model be used to identify biological entity activities?
Maciel, W. D., Faria-Campos, A., Gonçalves, M. A., & Campos, S. V. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-s4-s1 · Cited by 19
“We have also to cope with the coverage problem when looking for biological entity activities by searching several information sources such as experimental data [30,31], drug labels [32], scientific papers [5,12-20] and patents.”
BackgroundArtificial intelligence unifies knowledge and actions in drug repositioning
Yin, Z., & Wong, S. T. C. (2021) · Emerging Topics in Life Sciences · doi:10.1042/etls20210223 · Cited by 22
A compact review of progress and prospects of deep learning in drug discovery
Li, H., Zou, L., Kowah, J. A. H., He, D., Liu, Z., Ding, X., Wen, H., Wang, L., Yuan, M., & Liu, X. (2023) · Journal of Molecular Modeling · doi:10.1007/s00894-023-05492-w · Cited by 19
“[122] employed side effect and molecular fingerprint similarity to calculate the possibility of two drugs sharing the same target and successfully identifying new targets.”
BackgroundHuang, M.-S., Han, J.-C., Lin, P.-Y., You, Y.-T., Tsai, R. T., & Hsu, W. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae132 · Cited by 25
“Yang et al. [30] have extracted 3175 side-effect (SE)-disease relationships by combining SE-drug (888 drugs and 584 SEs in SIDER database [31]) and drug–disease (303 drugs and 145 diseases in PharmGKB [32]) relationships.”
MethodRamakrishnan, G., Chandra, N. R., & Srinivasan, N. (2015) · Molecular BioSystems · doi:10.1039/c5mb00476d · Cited by 21
Predictive Toxicology Approaches for Small Molecule Oncology Drugs
Maziasz, T. J., Kadambi, V. J., Silverman, L. R., Fedyk, E. R., & Alden, C. L. (2010) · Toxicologic Pathology · doi:10.1177/0192623309356448 · Cited by 22
“This best-case scenario is not often realized, and off-target pharmacological activity (also known as ancillary pharmacology) must also be addressed in optimization (Smith and Schmid 2006; Campillos et al. 2008; Smith et al. 2006).”
BackgroundJang, D., Lee, S., Lee, J., Kim, K., & Lee, D. (2015) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2015.12.003 · Cited by 23
A pathway profile-based method for drug repositioning
Ye, H., Yang, L., Cao, Z., Tang, K., & Li, Y. (2012) · Chinese Science Bulletin · doi:10.1007/s11434-012-4982-9 · Cited by 20
“…with known information regarding its targets [11]; (ii) identifying relationships between drugs based on the similarity of their side effects [12]; (iii) analyzing gene expression following drug treatment to infer new indications [13]; and (iv) building a background chemical-protein…”
BackgroundRandom walk with restart: A powerful network propagation algorithm in Bioinformatics field
Le, D. (2017) · NAFOSTED Conference on Information and Computer Science (NICS) · doi:10.1109/nafosted.2017.8108071 · Cited by 21
“, chemically and phenotypically similar drugs target to similar target proteins [34-38]).”
BackgroundMethodDeCoST: A New Approach in Drug Repurposing From Control System Theory
Nguyen, T. M., Muhammad, S. A., Ibrahim‐Shaikh, S., Ma, L., Guo, J., Bai, B., & Zeng, B. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00583 · Cited by 20
“, 2013) and from “lazy guiltby-association” (Campillos et al., 2008; Keiser et al., 2009; Iorio et al., 2010; Gottlieb et al., 2011) to “systematic model-based pattern matching,” such as the Broad Institute’s Connectivity Maps (CMAP), C2MAP, etc.”
BackgroundChen, H., & Zhang, Z. (2018) · IEEE Access · doi:10.1109/access.2018.2860632 · Cited by 22
Drug-Protein-Disease Association Prediction and Drug Repositioning Based on Tensor Decomposition
Wang, R., Li, S., Wong, M. H., & Leung, K. (2018) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm.2018.8621527 · Cited by 20
“Some additional information, such as structural similarity of drugs and proteins [4], [26] and side-effect information [27], are integrated into the networks to predict association/interactions more accurately.”
BackgroundHas Drug Repurposing Fulfilled Its Promise in Acute Myeloid Leukaemia?
Valli, D., Gruszka, A., & Alcalay, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061892 · Cited by 19
“Moreover, similar adverse effects caused by different drugs may suggest that they act on the same targets or pathways [12,13].”
BackgroundYANG, F., Xu, J., & Zeng, J. (2013) · Pacific Symposium on Biocomputing (PSB) · doi:10.1142/9789814583220_0015 · Cited by 28
Mapping small molecule binding data to structural domains
Krüger, F. A., Rostom, R., & Overington, J. P. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-s17-s11 · Cited by 19
“New targets have been predicted for FDA approved drugs through analysis of large-scale bioactivity databases [2] and side-effect data mined from package inserts [3].”
BackgroundNetwork Characteristic Analysis of ADR-related Proteins and Identification of ADR-ADR Associations
Chen, X., Liu, X., Jia, X., Tan, F., Yang, R., Chen, S., Liu, L., Wang, Y., & Chen, Y. (2013) · Scientific Reports · doi:10.1038/srep01744 · Cited by 19
“By identifying pairs of drugs in this network with distinct targets, the authors were able to assign the targets of one drug to the drugs it was connected to and subsequently validated the binding of the drug to its predicted secondary target 9 .”
BackgroundYin, L., Zheng, L., Xu, L., Dong, D., Han, X., Qi, Y., Zhao, Y., Xu, Y., & Peng, J. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-015-0579-6 · Cited by 19
Dhabhai, B., Dhakar, R., Ranga, V., Surolia, P. K., Menon, A. M., Sharma, N. K., Dakal, T. C., & Lohar, D. (2023) · Medinformatics · doi:10.47852/bonviewmedin32021408 · Cited by 19
Drug repurposing for glomerular diseases: an underutilized resource
Ng, M. S. Y., Kaur, G., Francis, R. S., Hawley, C. M., & Johnson, D. W. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00864-8 · Cited by 19
“Grouping drugs by ADRs revealed that the proton pump inhibitor rabeprazole also inhibited dopamine receptor D2 ( DRD2 ) and bound serotonin receptor 5-HT1D ( HTR1D ) 18 .”
Chen, L., Lu, J., Luo, X., & Feng, K. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.05.021 · Cited by 18
Network mirroring for drug repositioning
Park, S., Lee, D. A., & Shin, H. (2017) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-017-0449-x · Cited by 18
“…if two diseases share few number of similar therapies, then a drug used for a certain disease could be used for other disease [13], Campillos et al. (2008) predicted new targets for drugs by calculating similarities between diseases based on side effect that appears from injection of drug [14].”
BackgroundIn Silico Profiling of Clinical Phenotypes for Human Targets Using Adverse Event Data
Soldatos, T. G., Taglang, G., & Jackson, D. (2018) · Microarrays · doi:10.3390/ht7040037 · Cited by 20
“, [14,36,37] relied primarily on side-effect information coming from labels e.”
BackgroundDrug Side-Effect Prediction Via Random Walk on the Signed Heterogeneous Drug Network
Hu, B., Wang, H., & Yu, Z. (2019) · Molecules · doi:10.3390/molecules24203668 · Cited by 18
A comprehensive integrated drug similarity resource for in-silico drug repositioning and beyond
Azad, A., Dinarvand, M., Nematollahi, A., Swift, J., Lutze-Mann, L. H., & Vafaee, F. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa126 · Cited by 22
“, chemical structure characteristics [7, 21], protein targets [22, 23], side-effect profiles [6, 24], gene expression profiles [17, 25], and clinical information [2]—have been previously applied in drug-drug similarity analytics.”
BackgroundDrug Repurposing Based on Drug–Drug Interaction
Zhou, B., Wang, R., Wu, P., & De, K. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12378 · Cited by 21
“, at gene expression level (6) or at whole organism level (7)] has also emerged as a relatively new approach for inferring drug targets.”
BackgroundChen, H., & Zhang, Z. (2015) · BioMed Research International · doi:10.1155/2015/406463 · Cited by 19
“[19, 20] or side effect similarity [21] to enable the discovery of new uses for drugs.”
BackgroundLow, Y., Sedykh, A., Rusyn, I., & Tropsha, A. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666140506121116 · Cited by 20
Tanaka, Y., Chen, H. Y., Belloni, P., Gisladottir, U., Kefeli, J., Patterson, J., Srinivasan, A., Zietz, M., Sirdeshmukh, G., Berkowitz, J., et al. (2025) · Med · doi:10.1016/j.medj.2025.100642 · Cited by 17
Kwon, E., Mashelkar, K. K., Seo, J., Shin, Y.-Z., Sung, K., Jang, S. C., Cheon, S. W., Lee, H., Lee, H. W., Kim, G., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00332 · Cited by 18
An Algorithmic Framework for Predicting Side-Effects of Drugs
Atias, N., & Sharan, R. (2010) · Lecture notes in computer science · doi:10.1007/978-3-642-12683-3_1 · Cited by 17
Chen, Y., Cai, X., & Xu, R. (2015) · PubMed · Cited by 18
Copper-Mediated Reactions of Nitriles with Nitromethanes: Aza-Henry Reactions and Nitrile Hydrations
Kuwabara, J., Sawada, Y., & Yoshimatsu, M. (2018) · Organic Letters · doi:10.1021/acs.orglett.8b00058 · Cited by 17
Precision global health and comorbidity: a population-based study of 16 357 people in rural Uganda
Chami, G. F., Kabatereine, N. B., Tukahebwa, E. M., & Dunne, D. W. (2018) · Journal of The Royal Society Interface · doi:10.1098/rsif.2018.0248 · Cited by 17
Tabei, Y., Kotera, M., Sawada, R., & Yamanishi, Y. (2019) · BMC Systems Biology · doi:10.1186/s12918-019-0691-1 · Cited by 17
“On the other hand, the key idea behind the pharmacogenomic approach is that phenotypically similar drugs are predicted to interact with similar proteins, on the basis of drug side effects and/or protein sequences [9–12].”
BackgroundLiang, S., & Yu, H. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa495 · Cited by 17
Toward a Computational Ecotoxicity Assay
Kamerlin, N., Delcey, M. G., Manzetti, S., & van der Spoel, D. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00574 · Cited by 18
Durai, P., Ko, Y., Pan, C., & Park, K. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03643-x · Cited by 19
“The side-effect similarity of drugs is another approach to define whether two different drugs share the same or similar targets if they cause similar side-effects through drug-disease relationships [15, 16].”
BackgroundLactic Acidosis in Patients with Solid Cancer
Heneberg, P. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0267 · Cited by 19
“In addition to anti-acidic effects at the gastric level, they may affect the ATPases expressed by the cancer cells (209, 242), and they also affect signaling through dopamine and serotonin receptors (28).”
Screening for Safety‐Relevant Off‐Target Activities
Urbán, L., Whitebread, S., Hamon, J., Mikhailov, D., & Azzaoui, K. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch2 · Cited by 17
Binding sites in membrane proteins – Diversity, druggability and prospects
Adams, R. A., Worth, C. L., Günther, S., Dunkel, M., Lehmann, R., & Preißner, R. (2011) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2011.06.003 · Cited by 23
Publishing Chinese medicine knowledge as Linked Data on the Web
Zhao, J. (2010) · Chinese Medicine · doi:10.1186/1749-8546-5-27 · Cited by 17
Novel 7‐secretase inhibitors uncover a common nucleotide‐binding site in JAK3, SIRT2, and PS1
Wu, F., Schweizer, C., Rudinskiy, N., Taylor, D. M., Kazantsev, A. G., Luthi‐Carter, R., & Fraering, P. C. (2010) · The FASEB Journal · doi:10.1096/fj.09-148031 · Cited by 18
“Although this phenomenon sometimes results in undesired side effects, such activities can alternatively be of great utility, leading to new therapeutic indications for established drugs (1, 2).”
BackgroundCheminformatics-aided pharmacovigilance: application to Stevens-Johnson Syndrome
Low, Y., Caster, O., Bergvall, T., Fourches, D., Zang, X., Norén, G. N., Rusyn, I., Edwards, R., & Tropsha, A. (2015) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocv127 · Cited by 25
Li, W., Zhou, Y., Tang, G., Wong, N.-K., Yang, M., Tan, D., & Xiao, Y. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00325 · Cited by 17
Clinical side-effects based drug repositioning for anti-epileptic activity
Kumar, P., Sheokand, D., Grewal, A., Saini, V., & Kumar, A. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2199874 · Cited by 16
“The present study was designed and carried out to identify new comprehensive drugs as 1 st line AED(s) using the side-effect similarity pipeline (Campillos et al., 2008; Yang & Agarwal, 2011).”
MethodDrug Repurposing: Insights into Current Advances and Future Applications
Bhatia, T., & Sharma, S. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673266470231023110841 · Cited by 19
MPGraph: multi‐view penalised graph clustering for predicting drug–target interactions
Li, L. (2014) · IET Systems Biology · doi:10.1049/iet-syb.2013.0040 · Cited by 16
“Campillos et al. [6] proposed to use drug side effects to measure the similarity among drugs, which pave a new way to understand drugs.”
BackgroundMulti-pathway cellular analysis of compound selectivity
Hancock, M. K., Lebakken, C. S., Wang, J., & Bi, K. (2010) · Molecular BioSystems · doi:10.1039/c003669b · Cited by 16
Computational drug repurposing to predict approved and novel drug-disease associations
Khalid, Z., & Sezerman, O. U. (2018) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2018.08.005 · Cited by 17
Lakizadeh, A., & Babaei, M. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10382-z · Cited by 18
Capturing Structure−Activity Relationships from Chemogenomic Spaces
Wendt, B., Uhrig, U., & Bös, F. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci100270x · Cited by 16
A Systematic Investigation of Computation Models for Predicting Adverse Drug Reactions (ADRs)
Kuang, Q., Wang, M., Li, R., Dong, Y., Li, Y., & Li, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105889 · Cited by 18
“Computer-aided prediction of drug targets is similar to prediction of ADRs: there are close relationships between ADRs and drug targets that have been identified in biological systems [16,17].”
BackgroundNaveed, H., Hameed, U. F. S., Harrus, D., Bourguet, W., Arold, S. T., & Gao, X. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv477 · Cited by 17
Large-scale identification of adverse drug reaction-related proteins through a random walk model
Chen, X., Shi, H., Yang, F., Yang, L., Lv, Y., Wang, S., Dai, E., Sun, D., & Jiang, W. (2016) · Scientific Reports · doi:10.1038/srep36325 · Cited by 19
“For example, Campillos et al. used ADR similarity to infer drug targets, indicating that drugs that caused similar ADRs had similar protein binding profiles 9 .”
BackgroundGraph Convolutional Networks for Predicting Drug-Protein Interactions
Manoochehri, H. E., Pillai, A., & Nourani, M. (2019) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm47256.2019.8983018 · Cited by 18
“2 and 3 show that our methodology has better peformance in terms of AUROC and AUPR scores, respectively, compared to some state-of-the-art methods reported in literature, i.e. BLMNII [10], NetLapRLS [11], HNM [12] and CMF [13].”
MethodCao, D.-S., Jiang, S.-L., Guan, Y.-D., Chen, X.-S., Zhang, L.-X., Zhang, Y., Chen, A. F., Yang, J.-M., & Cheng, Y. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112421 · Cited by 16
Metadata
- Authors
- Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P.
- Affiliations
- European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, 69117 Heidelberg, Germany.
- Max Delbrück Center (DE)
- Corresponding author
- Kuhn, Michael
- Venue
- Science
- Published
- 2008-07-11
- Volume
- 321
- Issue
- 5886
- Pages
- 263-266
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2154896031
- Cited by
- 1,248
- References
- 27
- Citations by year
- 2026: 21 · 2025: 28 · 2024: 42 · 2023: 35 · 2022: 70 · 2021: 64 · 2020: 73 · 2019: 91 · 2018: 81 · 2017: 67 · 2016: 93 · 2015: 102 · 2014: 92 · 2013: 95 · 2012: 105
- FWCI
- 82.73
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Health Sciences › Medicine › Health Informatics › Biomedical Text Mining and Ontologies
- Keywords
- drug target identification, adverse drug reactions, phenotypic similarity, drug repurposing, drug-target interactions, marketed drugs
- MeSH terms
- Algorithms, Chemistry, Pharmaceutical, Drug Labeling, Drug Evaluation, Preclinical, Drug Therapy, Pharmaceutical Preparations, Humans, Probability, Proteins, Databases, Factual, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.